时代大考来临，华大基因（300676.SZ）的破局突围之路

Core Viewpoint - The concept of "self-controllable + domestic substitution" is emerging as a clear value anchor in the capital market amid global industrial chain restructuring and intensified technological competition. Companies with foundational innovation capabilities are demonstrating resilience through cycles [1]. Group 1: Company Performance - BGI Genomics reported a revenue of 3.867 billion yuan for the fiscal year 2024, showcasing its leadership in the global gene technology industry with comprehensive coverage of the entire industry chain and application scenarios [1]. - In the field of reproductive health, despite a declining birth rate, BGI Genomics achieved a year-on-year revenue growth of approximately 47.38% in newborn genetic disease screening and about 53.13% in clinical diagnosis of genetic diseases [2]. Group 2: Market Expansion and Strategy - The company has established a three-tier prevention system for birth defects covering pre-marital, pre-pregnancy, pregnancy, newborn, and childhood stages, successfully implementing prenatal screening and birth defect detection services in various cities [2]. - BGI Genomics is actively expanding its product layout and optimizing costs, extending genetic testing from secondary prevention to primary and tertiary prevention, thereby increasing market penetration and opening up new market spaces [2]. Group 3: Growth in Cancer and Chronic Disease Prevention - Significant growth was observed in the cancer and chronic disease prevention sectors, with colorectal cancer testing showing a remarkable year-on-year growth rate of 270.60% [3]. - The domestic high-throughput gene testing market for cancer reached a scale of 4.1 billion yuan in 2021, projected to grow to 49.1 billion yuan by 2030, with a CAGR of 32% from 2022 to 2030 [3]. Group 4: Technological Innovation and AI Integration - BGI Genomics has developed a differentiated layout in the AI + healthcare sector, utilizing AI technology to reconstruct the value chain of genetic testing [9]. - The company has launched the GeneT intelligent analysis system, significantly improving the efficiency of genetic variant interpretation, and established the ChatGeneT platform for public genetic health management [10]. Group 5: Strategic Advantages and Future Outlook - BGI Genomics leverages its technological foundation to create a comprehensive product matrix covering reproductive health, cancer screening, chronic disease prevention, and infection control, enhancing service accessibility through large-scale testing [7]. - The integration of hard technology and soft power through AI-driven innovations is expected to unlock dual benefits of increased healthcare spending and health consumption upgrades, positioning the company favorably in the market [12].